Sarah K Browne1, Steven M Holland. 1. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. brownesa@niaid.nih.gov
Abstract
PURPOSE OF REVIEW: Anticytokine autoantibodies are an important and emerging mechanism of disease pathogenesis. We will review the clinical and laboratory features of syndromes in which immunodeficiency is caused by or associated with neutralizing anticytokine autoantibodies. RECENT FINDINGS: A growing number of patients have been described who demonstrate unique infectious phenotypes associated with neutralizing autoantibodies that target a particular cytokine known to participate in host defense against the offending organism. Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma. SUMMARY: Anticytokine autoantibodies have manifestations that are diverse, ranging from asymptomatic to life-threatening. These emerging and fascinating causes of acquired immunodeficiency may explain some previously idiopathic syndromes.
PURPOSE OF REVIEW: Anticytokine autoantibodies are an important and emerging mechanism of disease pathogenesis. We will review the clinical and laboratory features of syndromes in which immunodeficiency is caused by or associated with neutralizing anticytokine autoantibodies. RECENT FINDINGS: A growing number of patients have been described who demonstrate unique infectious phenotypes associated with neutralizing autoantibodies that target a particular cytokine known to participate in host defense against the offending organism. Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma. SUMMARY: Anticytokine autoantibodies have manifestations that are diverse, ranging from asymptomatic to life-threatening. These emerging and fascinating causes of acquired immunodeficiency may explain some previously idiopathic syndromes.
Authors: Peter D Burbelo; Sarah K Browne; Elizabeth P Sampaio; Giuseppe Giaccone; Rifat Zaman; Ervand Kristosturyan; Arun Rajan; Li Ding; Kathryn H Ching; Arlene Berman; Joao B Oliveira; Amy P Hsu; Caitlin M Klimavicz; Michael J Iadarola; Steven M Holland Journal: Blood Date: 2010-08-17 Impact factor: 22.113
Authors: Tracey L Bonfield; Baisakhi Raychaudhuri; Anagha Malur; Susamma Abraham; Bruce C Trapnell; Mani S Kavuru; Mary Jane Thomassen Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-08-01 Impact factor: 5.464
Authors: Li Ding; Allen Mo; Kamonwan Jutivorakool; Minjal Pancholi; Steven M Holland; Sarah K Browne Journal: J Clin Immunol Date: 2011-12-06 Impact factor: 8.317
Authors: Gloria H Hong; Ana M Ortega-Villa; Sally Hunsberger; Ploenchan Chetchotisakd; Siriluck Anunnatsiri; Piroon Mootsikapun; Lindsey B Rosen; Christa S Zerbe; Steven M Holland Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: Julia E Rood; Sheila Rao; Michele Paessler; Portia A Kreiger; Niansheng Chu; Erietta Stelekati; E John Wherry; Edward M Behrens Journal: Blood Date: 2015-10-30 Impact factor: 22.113
Authors: H R Conti; O Baker; A F Freeman; W S Jang; S M Holland; R A Li; M Edgerton; S L Gaffen Journal: Mucosal Immunol Date: 2011-02-23 Impact factor: 7.313
Authors: Isha S Dhande; Sterling C Kneedler; Aniket S Joshi; Yaming Zhu; M John Hicks; Scott E Wenderfer; Michael C Braun; Peter A Doris Journal: Physiol Genomics Date: 2019-10-14 Impact factor: 3.107
Authors: Chunsheng Zhou; Leticia Monin; Rachael Gordon; Felix E Y Aggor; Rami Bechara; Tara N Edwards; Daniel H Kaplan; Sebastien Gingras; Sarah L Gaffen Journal: J Immunol Date: 2020-06-29 Impact factor: 5.422
Authors: Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke Journal: MAbs Date: 2014 Impact factor: 5.857
Authors: Shrinivas Bishu; Nydiaris Hernández-Santos; Michelle R Simpson-Abelson; Anna R Huppler; Heather R Conti; Nico Ghilardi; Anna J Mamo; Sarah L Gaffen Journal: Infect Immun Date: 2013-12-30 Impact factor: 3.441